ARNA Arena Pharmaceuticals, Inc.

1.29
+0  (2%)
Previous Close 1.27
Open 1.27
Price To book 7.74
Market Cap 316.65M
Shares 245,469,000
Volume 1,884,094
Short Ratio 4.76
Av. Daily Volume 2,110,930

SEC filingsSee all SEC filings

  1. 8-K - Current report 17767548
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17767533
  3. 8-K - Current report 17765364
  4. 424B5 - Prospectus (Rule 424(b)(5)) 17764621
  5. PRE 14A - Other preliminary proxy statements 17759343

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated March 2017.
Etrasimod
Pyoderma gangrenosum (PG)
Phase 2 trial initiated March 2017.
Etrasimod
Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD)
Approved June 27, 2012.
Lorcaserin
Obesity
Phase 2 to be initiated 2017.
APD371
Pain associated with Crohn's disease
Phase 2 initiated March 2014. Data released Nov 2014
Lorcaserin
Smoking cessation
Phase 2 data due by the end of 2017.
Etrasimod
Ulcerative colitis
Phase 2 data due mid-2017.
Ralinepag
Pulmonary Arterial Hypertension

Latest News

  1. Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
  2. Arena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : April 19, 2017
  3. Arena Pharma (ARNA) Down After Underwritten Public Offering
  4. Biotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena Pharmaceuticals and Cytokinetics
  5. Why Is Arena Pharmaceuticals (ARNA) Down 11.3% Since the Last Earnings Report?
  6. Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers
  7. Why Arena Pharmaceuticals Stock Is Getting Hammered Today
  8. Arena Pharmaceuticals Sinks After Announcing Secondary Offering
  9. Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : April 18, 2017
  10. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  11. Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology
  12. The State of Play in Axovant Sciences
  13. Why Arena Pharmaceuticals Stock Slimmed Down in March
  14. ETFs with exposure to Arena Pharmaceuticals, Inc. : April 7, 2017
  15. New Strong Sell Stocks for April 6th
  16. Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and Immunomedics
  17. Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : March 28, 2017
  18. ETFs with exposure to Arena Pharmaceuticals, Inc. : March 27, 2017
  19. Arena Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference on April 4th
  20. Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017